Impact of an Information Sheet Given to Parents After an Initial Consultation for a Simple Febrile Seizure at Strasbourg University Hospital

NCT ID: NCT07335640

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-11

Study Completion Date

2026-06-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Simple febrile seizures (SFS) are a very common phenomenon (2-5% of children), mostly without serious consequences for the child or their development, but extremely anxiety-provoking for parents, who develop a "fear of fever" for fear of a recurrence, and request numerous additional tests, not justified according to current guidelines, after a first episode of SFS.

Educating parents about these fever-related crises and fever management, and standardizing the information provided through an explanatory sheet implemented at the SAUP in July 2023, would help reduce consultations for recurrent simple febrile crises, as well as early consultations for isolated fever (reflecting parental anxiety caused by these crises).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Febrile Crisis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Child aged between 9 months and 5 years at the time of consultation at the SAUP (emergency pediatric unit)
* First visit to the SAUP for a simple febrile seizure
* Meeting the clinical criteria for FCS:

* Generalized seizure lasting less than 15 minutes
* No post-critical deficit
* No recurrence of seizures within 24 hours
* No personal history of neurological disorders
* Occurrence between January 1, 2022, and May 1, 2025
* First or second episode of FSFS at the time of consultation
* Presence of one of the two parents during the consultation at the SAUP

Exclusion Criteria

* Patient already seen at the SAUP for FCS
* Child who has already had more than two simple febrile seizures at the time of their visit to the emergency department.
* Child who does not meet the criteria for simple febrile seizures:
* aged less than 9 months or more than 5 years at the time of diagnosis.
* Non-febrile seizure
* Focal seizure
* Seizure duration \>15 min
* Presence of post-critical deficit
* Multiple seizures within 24 hours
* Personal neurological history.
* Seizure occurring outside the period of interest (January 1, 2022 to May 1, 2025)
* Absence of parents during the SAUP consultation
Minimum Eligible Age

9 Months

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarah Baer, MD

Role: CONTACT

33 3 88 12 63 98

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sarah Baer, MD

Role: primary

33 3 88 12 63 98

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9695

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.